论文部分内容阅读
目的:观察恩度联合EP方案治疗晚期小细胞肺癌的疗效及安全性。方法:47例符合入组条件的晚期小细胞肺癌患者随机分为2组:对照组(25例)采用EP方案;实验组(22例)在对照组的基础上于每周期化疗第1-14天给予恩度15mg/d,21d为1个周期,每2周期评价疗效。观察两组患者的毒副反应、客观缓解率、无进展生存时间以及总生存时间的差异。结果:对照组客观缓解率40%,实验组缓解率为68%,中位无进展时间分别为6.4个月和5.5个月,中位生存期分别为10.9个月和10个月,差异有统计学意义(P<0.05)。两组不良反应发生率无明显差别(P>0.05)。结论:EP化疗联合恩度可提高小细胞肺癌患者近期疗效及远期生存,且不良反应小,安全性好。
Objective: To observe the efficacy and safety of Endue combined with EP regimen in the treatment of advanced small cell lung cancer. Methods: Forty-seven patients with advanced small cell lung cancer who were eligible for inclusion were randomly divided into two groups: control group (n = 25) received EP regimen; experimental group (n = 22) Day to give a degree of 15mg / d, 21d for a cycle, evaluate the efficacy of every 2 cycles. Toxic side effects, objective response rates, progression-free survival and overall survival were observed in the two groups. Results: The objective response rate was 40% in the control group and 68% in the experimental group. The median progression-free time was 6.4 months and 5.5 months respectively. The median survival time was 10.9 months and 10 months respectively, with statistical differences Significance (P <0.05). No significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion: EP chemotherapy combined with Endue can improve the short-term curative effect and long-term survival of patients with small cell lung cancer with less adverse reactions and good safety.